SenoGuard
OperatingSenoGuard, Inc
Biotech · Seal Beach, CA
Non-radiation breakthrough in breast cancer treatment
Financials
FY2023–FY2024 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps markedA dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Team
5 people
Implemented disruptive technologies at corporate healthcare companies such as JNJ & AMO, as well as early-stage privately held companies that changed paradigms and became standard of care. Executed new breast cancer molecular testing that's now standard.
Medical device/cryoablation engineer with over 30 years experience and 94 issued U.S. patents. Designed and launched several novel cryo-energy medical devices. Considered to be one of few experts globally in advanced cryoablation for medical devices.
Associate Professor Surgery Rush University as professor of breast cancer surgery Chief clinical advisor for several breast cancer start-ups. Former Medical Director of Sanarus, Advisor to Xoft and Kubtec; all successful start-ups in breast cancer space.
25+ years experience as a financial professional, including roles in public accounting, global investment banking and leadership roles in both early stage and middle-market life sciences ventures.
Pioneer in cryomedicine with 75+ patents and 100+ publications. Founder of CPSI Biotech and co-developer of several novel cryoablation systems. President-Elect of the Society for Cryobiology, with experience across biotech, R&D, and FDA processes.
Names and titles as disclosed on SEC Form C, WeFunder. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
never closed a Reg CF raise
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.